## Page 1

doi: 10.1111/fcp.12186
Treatment of anxiety and depression:
REVIEW
ARTICLE
medicinal plants in retrospect
James O. Fajemiroye, Dayane M. da Silva*, Danillo R. de Oliveira,
Elson A. Costa
DepartmentofPharmacology,InstituteofBiologicalSciences,FederalUniversityofGoi(cid:1)as,74001-970,Goi^ania,GO,
Brazil
Keywords ABSTRACT
anxiety
Anxiety and depression are complex heterogeneous psychiatric disorders and lead-
depression
medicinalplants ing causes of disability worldwide. This review summarizes reports on the funda-
Pimentapseudocaryophyllus mentals, prevalence, diagnosis, neurobiology, advancement in treatment of these
preclinicalmodels diseases and preclinical assessment of botanicals. This review was conducted
through bibliographic investigation of scientific journals, books, electronic sources,
unpublished theses and electronic medium such as ScienceDirect and PubMed. A
Received22September2015;
number of the first-line drugs (benzodiazepine, azapirone, antidepressant tricyclics,
revised8January2016;
monoamine oxidase inhibitors, serotonin selective reuptake inhibitors, nora-
accepted2February2016
drenaline reuptake inhibitors, serotonin and noradrenaline reuptake inhibitors,
etc.) for the treatment of these psychiatric disorders are products of serendipitous
*Correspondenceandreprints:
discoveries. Inspite of the numerous classes of drugs that are available for the
daymoress@gmail.com
treatment of anxiety and depression, full remission has remained elusive. The
emerging clinical cases have shown increasing interests among health practitioners
and patients in phytomedicine. The development of anxiolytic and antidepressant
drugs of plant origin takes advantage of multidisciplinary approach including but
not limited to ethnopharmacological survey (careful investigation of folkloric appli-
cation of medicinal plant), phytochemical and pharmacological studies. The selec-
tion of a suitable plant for a pharmacological study is a basic and very important
step. Relevant clues to achieving this step include traditional use, chemical compo-
sition, toxicity, randomized selection or a combination of several criteria. Medicinal
plants have been and continue to be a rich source of biomolecule with therapeutic
values for the treatment of anxiety and depression.
pharmaceutical agents based on its popular use is by
INTRODUCTION
far the most effective strategy [4]. The plants that have
The development of anxiolytic and antidepressant been used popularly for years constitute the most obvi-
drugs of plant origin involves ethnopharmacological ous source of botanical material for the investigation of
survey (careful investigation of folkloric application of therapeutically effective drugs. The collection of plant
medicinal), phytochemical and pharmacological studies material, identification and deposition of specimen in
(Figure 1). The selection of a suitable plant for a phar- the herbarium are generally followed by quantitative
macological study is a very important step. Relevant and qualitative analyses with different techniques
clues to achieving this step include traditional use, including thin-layer chromatography, column chro-
chemical composition, toxicity, randomized selection or matography, high-performance liquid chromatography,
a combination of several criteria [1–3]. Selection of nuclear magnetic resonance, among other phytochemi-
medicinal plants with a view to discovering new cal techniques.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
198 Fundamental&ClinicalPharmacology30(2016)198–215

## Page 2

Anxiety, depression and medicinal plants 199
1
Ethnopharmacological study Collection and identification
2
Fractionation
Extraction
Purification and Isolation
3
Pharmacological study Chemical elucidation
Structural modification Phytochemical study
4
Synthesis
Ex vivo, in vitro, in vivoassays (preliminary pharmacological screening, classical animal models of anxiety: light dark box test,
elevated plus-maze, open field, etc. Classical animal models of depression: forced swimming test, tail suspension test, etc).
Figure1 Hypotheticalmodelforthediscoveryofmedicinalplantextractsandphytoconstituentswithanxiolyticand/orantidepressant
property(ies).(i)Selectionofmedicinalplantwithanxiolyticand/orantidepressantpotentialbasedonlocalreports;(ii)Preparationof
standardcrudeextracts;(iii)Phytochemicalstudies(sequentialpartitioningofcrudeextracts,purificationandisolationof
phytoconstituents,chemicalelucidationorcharacterizationoftheisolates,structuralmodificationsorsynthesisofanewcompound
basedonthechemicalstructureofisolates;(iv)Pharmacologicalstudyofanti-anxietyandantidepressantpropertiesofstandardcrude
extracts,fractions,isolatedcompoundsorderivatives.Exvivo,invitro,invivoassays(preliminarypharmacologicalscreening,classical
animalmodelsofanxiety:lightdarkboxtest,elevatedplus-maze,openfield,etc.Classicalanimalmodelsofdepression:forcedswimming
test,tailsuspensiontest,etc.).
Following the ethnopharmacological survey and population suffer from various forms of anxiety disor-
phytochemical studies, biological investigations of ders with such symptoms as high blood pressure, ele-
botanicals are inevitable. Animal models of anxiety vated heart rate, sweating, fatigue, unpleasant feeling,
and depression have played relevant roles in the devel- tension, irritability and restlessness [9,10]. These symp-
opment of new drugs [5,6]. A well-validated test could toms constitute negative impact to the patient, families
lead to consistent preclinical and clinical findings of and society. In the absence of treatment, patients
novel anxiolytic and antidepressant drugs. In recent would progress to depression and sometimes contem-
times, some of the traditional preclinical approaches plate suicide [11]. Depression that was the fourth lar-
have witnessed modifications and innovations. This gest cause of disease’s burden worldwide in 1990 is
review sought to summarize background of anxiety expected to be the second largest by 2020 [12]. The
and depression, pharmacological treatments, medicinal prevalence of major depressive disorder in community
plants with anti-anxiety and antidepressant properties samples ranges from 5 to 9% for women and 2 to 3%
as well as preclinical strategies for the investigation of for men [13]. Symptoms of depression include low, sad
extract or phytoconstituents with potential anxiolytic or depressed mood and/or loss of interests or pleasure
and/or antidepressant activity (ies). in previously enjoyable activities [14].
Prevalence and diagnosis of anxiety and Neurobiology of anxiety and depression
depression An increase in the prevalence of these mental illnesses
Anxiety and depression are widely acclaimed as psychi- with mind-boggling questions in respect of its patho-
atric disorders of global concern that are capable of genesis [15] has kept researchers groping in the dark
compromising human welfare [7]. Anxiety disorder is for years. The comprehension of neurobiology of these
characterized by cognitive, somatic, emotional and diseases is important to effective treatment. The under-
behavioural alterations [8]. About 4–6% of the global standing of neural mechanism of drugs as well as the
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

### Table 1 (Page 2)

| 1
Ethnopharmacological study Collection and identification
2
Fractionation
Extraction
Purification and Isolation
3
Pharmacological study Chemical elucidation
Structural modification Phytochemical study
4
Synthesis
Ex vivo, in vitro, in vivoassays (preliminary pharmacological screening, classical animal models of anxiety: light dark box test,
elevated plus-maze, open field, etc. Classical animal models of depression: forced swimming test, tail suspension test, etc).
igure1 Hypotheticalmodelforthediscoveryofmedicinalplantextractsandphytoconstituentswithanxiolyticand/orantidepressant
roperty(ies).(i)Selectionofmedicinalplantwithanxiolyticand/orantidepressantpotentialbasedonlocalreports;(ii)Preparationof
tandardcrudeextracts;(iii)Phytochemicalstudies(sequentialpartitioningofcrudeextracts,purificationandisolationof
hytoconstituents,chemicalelucidationorcharacterizationoftheisolates,structuralmodificationsorsynthesisofanewcompound
asedonthechemicalstructureofisolates;(iv)Pharmacologicalstudyofanti-anxietyandantidepressantpropertiesofstandardcrude
xtracts,fractions,isolatedcompoundsorderivatives.Exvivo,invitro,invivoassays(preliminarypharmacologicalscreening,classical
nimalmodelsofanxiety:lightdarkboxtest,elevatedplus-maze,openfield,etc.Classicalanimalmodelsofdepression:forcedswimmin
est,tailsuspensiontest,etc.). | Collection and identification |
| --- | --- |

## Page 3

200 J.O. Fajemiroye et al.
prediction of possible response of patients to anxiolytic characterizedwithcasesofsideeffects,forexampleben-
and antidepressant drugs could be greatly enhanced zodiazepineswhichinducesedation,ataxia,andamnesia
through the knowledge of the neurobiology [16]. amongothers(Table I).Despitetheadvancesinthetreat-
The role of the limbic system in emotion was identi- ment of depression and anxiety, clinical needs of
fied by James Papez in early 1930. He described the substantial number of patients are yet to be met. The
‘system of emotion’ as one of the major pathways of efficacy, duration of effects and side effects of available
the limbic systems that connect groups of brain struc- drugshaveconstitutedseriousconcernandtheneedfor
tures (cingulate gyrus, hippocampus, hypothalamus newer drugs. The diversity in neural targets makes
and nuclei thalamus) around the brainstem [17]. Dre- phytomedicine a promising candidate for the treatment
vets [18] hypothesized anatomical circuits involving ofthesediseases.
medial prefrontal cortex (MPC) and amygdala within
the context of a model in which the dysfunction of
MEDICINAL PLANTS
MPC results in the disinhibition of limbic transmission
over the amygdala. The dysregulation of neurochemi- Popular application and therapeutic value of
cal function, cognitive, endocrine, immune and auto- medicinal plants
nomic systems [19] are critical alterations in the The use of medicinal plants in the prevention and
homoeostatic processes capable of causing anxiety and treatment of diseases has been reported time immemo-
depression. The changes in neuronal processes could rial [34,35]. The impact generated by the discovery of
result in structural changes, disruption of neural net- naturally occurring compounds, such as antibiotics
works and plasticity [20], impairment of neural func- (e.g. penicillin, tetracycline, erythromycin), anticancer
tion and chemical imbalance in the brain. drugs (e.g. vinblastine, vincristine, paclitaxel), cardiac
glycosides (digoxin), among others, has attracted a lot
Pharmacological treatment of anxiety and of interests [36]. Currently, the therapeutic value of
depression medicinal plants is reflected in the percentage of medi-
Despite the availability of numerous classes of drugs for cal prescriptions of which 25% are derived from vegetal
the treatment of anxiety and depression, full remission species [37]. Across the world, traditional medicine
of disease symptom has remained elusive. Clinical use (TM) serves either as the mainstay of healthcare deliv-
of these drugs (Table I) is limited by their characteristic ery or complement to it [38]. In some countries, TM or
side effects and poor tolerability profile. Some of the nonconventional medicine may be termed complemen-
first-line anxiolytic and antidepressant drugs enhance tary and alternative medicine (CAM) which is an
monoaminergic function by inhibiting the enzyme important and often underestimated part of health ser-
responsible for the breakdown of monoamines (nore- vices [39]. TM has a long history of use in health
pinephrine, serotonin and dopamine) and block reup- maintenance, disease prevention and treatment. TM is
take of monoamines to increase their concentration at the total sum of knowledge, skill, and cultural practices
the synaptic cleft. Table I displays several other mecha- based on the theories, beliefs and indigenous experi-
nisms of anti-anxiety and antidepressant properties of ences whether explicable or not towards diagnosis and
drugs. treatment of physical and mental illness [40].
First-line anxiolytic and/or antidepressant drugs are According to the World Health Organization (WHO)
widely sought after by patients with or without pre- in the guidelines on the conservation of medicinal
scription. Benzodiazepines that are the most commonly plants, about three-quarters of the world population
used anxiolytic drugs potentiate the inhibitory depend on TMs for their primary healthcare needs [38].
GABAergic transmission [21]. Interestingly, the actions TheintegrationofCAMandconventionalmedicineindi-
of some anxiolytic drugs with antidepressant activity cates inherent value of CAM in primary healthcare
are an indication that these psychiatric diseases could needs [41,42]. In 2008, approximately 38% of Ameri-
have overlapping pathophysiology. The action of can adults (about 4 in 10) and approximately 12% of
serotonin agonists such as buspirone and gepirone on American children (about 1 in 9) are using some form
presynaptic and postsynaptic 5-hydroxytryptamine-1A ofCAM.Thefollowingyear,salesofherbalsupplements
(5-HT ) receptors predicts both anxiolytic and in the mass market retail channel grew 15% to nearly
1A
antidepressant activities [22]. Meanwhile, some of the $900 million representing over 17% of the total $5 bil-
drugs that are currently on the counter seem to be lion consumer sales [43]. In 2012, sales of herbal
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 4

Anxiety, depression and medicinal plants 201
TableI Somedrugswithanxiolyticandantidepressantproperties[23–33].
Classes Drugs Sideeffects Mechanism
Anxiolyticdrugs
Barbiturate Amytal Somnolence,headache,confusion,hyperkinesias,ataxia,etc. Theinteractionofbarbiturates
Seconal Dizziness,headache,confusion,bradycardia,ataxia,etc. withGABAAreceptors
Tuinal Drowsinessanddizziness,stomachupset,headache,weakness,etc. decreasestherateof
Phenobarbital Clumsiness,dizziness,excessivedaytimedrowsiness,etc. dissociationofGABAfrom
Nembutal Confusion,hallucinations,shallowbreathing,weakpulse,etc. thesereceptors,thereby
increasingthedurationof
theGABA -activatedopening
A
ofchloridechannels.
BZD Alprazolam Confusion,hyperactivity,agitation,hostility,chestpain,etc. TheseagentsbindtoBZDsite
Clonazepam Confusion,hallucinations,painfulordifficulturination,etc. ofGABA increasingthe
A
Diazepam Sedation,dependence,ataxia,amnesia,slurredspeech,etc. frequencyofchloride
Lorazepam Drowsiness,sleepiness,fatigue,confusion,amnesia,etc. channelopening,thereby
potentiatinginhibitoryeffect
ofGABA.
Antihistamines Hydroxyzine Dizziness,hypotension,constipation,drymouth,confusion,etc. HistamineH1receptor
Chlorpheniramine Constipation,diarrhoea,dizziness,drowsiness,drymouth,etc. antagonists.
Azapirone Buspirone Dizziness,nausea,insomnia,nervousness,chestpain,etc. Partialagonistof5-HT 1A
receptor.
Anxiolyticandantidepressantdrugs
MAOI Iproniazid Sexualdysfunction,drowsiness,drymouth,itching,hepatitis,etc. MAO-AandMAO-Binhibition
Isocarboxazid Faintness,numbness,orthostatichypotension,photophobia,etc. MAO-AandMAO-Binhibition
Tranylcypromine Allergicreaction,tremor,blurredvision,nausea,vomiting,etc. MAO-AandMAO-Binhibition
Phenelzine Dizziness,headache,constipation,drymouth,hyperactive,etc. MAO-AandMAO-Binhibition
Moclobemide Irregularheartbeats,blurredvision,highbloodpressure,etc. MAO-Ainhibition
TCAs Imipramine Dizziness,impotence,drymouth,nightmares,pupildilation,etc. Inhibitionof5-HTandNE
Desipramine Constipation,diarrhoea,dizziness,drymouth,weightchanges,etc. reuptakebyblockingthe
Clomipramine Drowsiness,drymouth,headache,irritability,tiredness,etc. SERTandNET.
Amitriptyline Chestpain,sweating,generalillfeeling,numbness,etc.
Nortriptyline Agitation,hallucinations,overactivereflexes,confusion,etc.
SSRIs Fluoxetine Nausea,vomiting,diarrhoea,sweating,confusion,agitation,etc. Selectiveinhibitionof5-HT
Paroxetine Sexualdysfunction,heartburn,runnyorstuffynose,etc. reuptake
Sertraline Decreasedappetiteorweightloss,diarrhoeaorloosestools,etc.
Citalopram Sexualdysfunction,sleepinessorunusualdrowsiness,etc.
Fluvoxamine Constipation,headache,tiredness,sexualdysfunction,etc.
Antagonist/reuptake Nefazodone Hepaticfailure,nausea,blurredvision,posturalhypotension,etc. Blocks5-HT2receptorsand
inhibitor inhibitsneuronalreuptake
of5-HTandNEtoprolong
theirconcentrationinthe
synapticcleft
a-antagonist Mirtazapine Agitation,hallucinations,fever,headache,lossofcoordination,etc. Enhancesmonoaminergic 2
functionbypresynaptic
a 2-receptorblockadeto
disinhibit5-HTandNErelease
SNRI Venlafaxine Nausea,drymouth,dizziness,decreasedlibido,delirium,etc. Enhancesmonoaminergic
Duloxetine Tremors,convulsions,reducedactivity,slowpupillaryresponse,etc. functionbyinhibiting
neuronalreuptakeof5-HT
andNE
NDRI/ATCA Amineptine Acne,nervousness,insomnia,suicidaltendency,etc. Enhancesmonoaminergic
Bupropion Headache,insomnia,dysphoria,seizure,drymouth,etc. functionbyinhibiting
neuronalreuptakeofDA
andNE
Someofthedrugsonthistableelicitmultipleeffectswithpluralmechanismofaction.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 5

202 J.O. Fajemiroye et al.
dietarysupplementsintheUSAincreasedby5.5%[43]. Administration (FDA) in the United States during
Despite the great potential of medicinal plants as a 12-year period (1983–1994) and found that 157 of
source of new molecules, there is still a dearth of com- 520 drugs (30%) approved were natural products or
prehensive studies. The few studies on these medicinal their derivatives [46]. In the expanded version of this
plantsarelargelyatpreliminarystage[44,45]. study by Newman and colleagues [47] during a 22-
year period (1981–2002), it was particularly evident
Relevance of medicinal plants to the development that over 60 and 75% of these drugs in the areas of
of psychoactive drugs cancer and infectious diseases, respectively, were of
Nowadays, there seems to be overdependence on syn- natural origin.
thetic drugs for curing or alleviating certain emotional Studies have demonstrated that many phytochemi-
disorders. Meanwhile, researches have shown that cals such as saponins [48], alkaloids [49,50], polyphe-
many people look for herbal products for the treatment nols [51], triterpenoid [52], essential oil [53,54], fatty
of different kinds of psychiatric disorders. In recent acid [55], flavonoids [56] possess anxiolytic- and
times, scientific studies are being focused on the valida- antidepressant-like effects. In this context, it is worth
tion of popularly acclaimed medicinal plants with psy- mentioning the discovery of new drugs with anxiolytic
choactive properties. Important compounds acting on and antidepressant activities. During 1981–2002, 10
the central nervous system have been isolated from new chemicals entities with anxiolytic activity and 21
plant species, and some of them are now being used with antidepressant activity were developed from
clinically (in their natural or modified form) for various natural or synthetized origin [47].
CNS disorders as shown in Figure 2 and Table II.
In the United States, Cragg and associates conducted
an analysis of drugs approved by the Food and Drug
HC 3 N H
HO
O O H OH
N CH O O N CH O
3 3
H
HO O O O
CH
3
(a) D-(-)-Morphine (b)Cocaine (c) Scopolamine
Molecular Formula: C 17 H 19 NO 3 Molecular Formula: C 17 H 21 NO 4 Molecular Formula: C 17 H 21 NO 4
Average mass: 285.338 Da Average mass: 303.353 Da Average mass: 303.353 Da
N
NHCH
3 H
HO H N
CH 3 H
N H
O H O H O O P O O H H3C N CH3
(d)Ephedrine (e)(-)-Strychnine (f)Psilocybin
Molecular Formula: C 10 H 15 NO Molecular Formula: C 21 H 22 N 2 O 2 Molecular Formula: C12H17N2O4P
Average mass: 165.232 Da Average mass: 334.412 Da Average mass: 284.248 Da
OH OH O OH H 3C H 3C CH3
OH
H 3C O
CH3
O
N CH
H
H
3
3
C
C O
O
H
H
O
O CH3 CH3
O
3 CH3
H 3 C
OH O OH
H 3C CH3 CH3
(g)(-)-Galanthamine (h)Hypericin (i)Hyperforin Figure2 Somecommonpsychoactive
Molecular Formula: C 17 H 21 NO 3 Molecular Formula: C 30 H 16 O 8 Molecular Formula: C 35 H 52 O4 secondarymetabolitesisolatedfrom
Average mass: 287.353 Da Average mass: 504.443 Da Average mass: 536.785 Da medicinalplants.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 6

Anxiety, depression and medicinal plants 203
CH
2
HC O CH 3 3 H
H HO
H
CH
3
HO OH
O N
O H 3 C CH 3
O OH
CH
(j) Cannabidiol 3 (k) Pipermethystine (l) Valerenic acid
Molecular Formula: C H O Molecular Formula: C H NO Molecular Formula: C H O
21 30 2 16 17 4 15 22 2
Average mass: 314.462 Da Average mass: 287.310 Da Average mass: 234.334 Da
OH O CH
O N 3 N H 3 C H CH
HC 3 3
HO O H 3 C N N H
O CH 3 HC (m) Chrysin (n) Caffeine (o) (-)-ß-ca 2 ryophyllene
Molecular Formula: C H O Molecular Formula: CH NO Molecular Formula: C H
15 10 4 8 10 4 2 15 24
Average mass: 254.238 Da Average mass: 194.191 Da Average mass: 204.351 Da
H 3 C CH H 3 O
O O
H H
H
H HCH
3 H
O
H H
N CH
3
HO H OH O H O O
OH CH
CH 3 O O H3 O O
CH 3 H 3 C H O O
(p) 26-deoxyactein (q)(+)-Bicuculline
Molecular Formula: C H O Molecular Formula: C H NO
37 56 10 20 17 6
Average mass: 660.834 Da Average mass: 367.352 Da
O
O
HC N HC
3 O CH 3 O
3
O H N O H 3 C
HC H 3 C N
3 O O N H CH 3 O O O
H 3 C O CH 3 O
(r) Yagonine (s) (-)-Physostigmine (t) Dihydromethysticin
Molecular Formula: C H NO Molecular Formula: C H NO Molecular Formula: C H O
20 17 6 15 21 3 2 15 16 5
Figure2 (Continued) Average mass: 367.352 Da Average mass: 275.346 Da Average mass: 276.284 Da
Plant species with anti-anxiety and/or Surveillance (ANVISA) included products that are
antidepressant properties derived from Passiflora incarnata, Piper methysticum,
Regulatory bodies provide definitions for herbal medic- Valeriana officinalis, Cimicifuga racemosa for the treat-
inal products. They are those obtained with exclusive ment of anxiety disorders and/or depression. Like
use of botanicals with recognized efficacy, acceptable ANVISA, European Medicines Agency (EMA) included
level of safety, scientific data, preclinical (pharmaco- Hypericum perforatum L. (St. John’s Wort, SJW),
logical and toxicological studies) and clinical publica- Melissa officinalis L. (Melissa leaf), V. officinalis L.
tions [57,58]. Some herbal medicines have been (Valerian Root) among others in the list of Herbal
approved by regulatory bodies for treating mental dis- medicines for the treatment of mental stress and mood
orders. In Brazil, the National Agency of Sanitary disorders [59].
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on [27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 7

204 J.O. Fajemiroye et al.
TableII Drugsthatareisolatedfromplantswithbiological sizeanddosesofstandardizedextract.Allthesevariables
activitiesontheCNS. jointly contribute to the lack of consensus among
researchers regarding the use of herbal derivatives from
Metabolites Isolatedby Year
H. perforatum.
Morphine Sertu€rner 1805
Strychnine PelletierandCaventou 1818 Passiflora incarnata L. (Passion flower)
Caffeine FriedliebandFerdinandRunge 1819 The herbal medicines derived from P. incarnata are pre-
Cocaine AlbertNiemann 1859
scribed in many parts of the world to treat some CNS
Physostigmine JobstandHesse 1864
disorders. This plant is used for the treatment of insom-
Scopolamine AlbertLadenburg 1881
nia and anxiety disorders in Brazil, Europe and USA
Ephedrine Nagai 1885
Methystine Pomeranz 1889 [57,70]. Clinical applications of this species worldwide
Chrysin Semrau 1889 have led to its inclusion in British Herbal
Caryophyllene Liebig’sAnnalen 1892 Pharmacopoeia (1983), Homoeopathic Pharmacopoeia
Yagonine Reidel 1904 of India (1974), United States Homoeopathic Pharma-
Dihydromethysticin Winzheimer 1908 copoeia (1981), Pharmacopoeia Helvetica (1987), and
Bicuculline Mansk 1932
in the pharmacopoeia of Egypt, France, Germany and
Hypericin Brockmann,Haschad,MaierandPohl 1939
Switzerland [71]. Phytochemical studies of P. incarnata
Cannabidiol Adams,PeaseandClark 1940
Psilocybin AlbertHoffman 1943 showed the presence of flavonoids (orientin, isoorientin,
Galantamine Mashkovsky 1951 vitexin, isovitexin and chrysin), cyanogenic glycosides
Valerenicacid StollandSeebeck 1957 and indole alkaloids [72,73]. Zanoli et al. [74] and
Hyperforin Gurevichandcolleagues 1971 Brown et al. [75] reported the anxiolytic-like effect of
27-Deoxyactein Berger,JuniorandKopanski 1988
chrysin in rats, which might be due a benzodiazepine
receptors ligand [76]. However, the anxiolytic effects of
Hypericum perforatum L. (SJW) P. incarnata do not seem to be associated solely chrysin
Hypericum perforatum popularly known as SJW is a or another compound, but it seems associated with
perennial herb native to Europe [60]. This species has phytocomplex (different phytoconstituents) acting in a
been studied extensively and described in ‘American synergistic manner [70].
HerbalPharmacopoeiaTM,TherapeuticCompendiumTM
andin American BotanicalCouncil’.Theherbal medici- Piper methysticum G. Foster (Kava)
nes derived from H. perforatum are prescribed around Regulatory bodies of herbal medicines have included
the world for moderate depressive states, anxiety and P. methysticum G. Foster (kava) for the symptomatic
other disorders of CNS [61]. Hypericin and hyperforin treatment of mild-to-moderate stages of anxiety [77].
have been associated with the effect of H. perforatum. Thisspecieshasalsobeenindicatedfordepression,anxi-
Many researchers suggested that hypericin which inhi- ety, insomnia and attention deficit/hyperactivity disor-
bitsMAO-AandMAO-Benzymeswithstrongaffinityfor der comorbid [78]. Kava is a South Pacific plant with
sigma receptors to regulate dopamine levels is the con- traditional application as an anxiolytic. Kavalactones
stituent of SJW that is responsible for antidepressant (or kavapyrones) such as kawain, dihydrokavain,
activity of this species [61]. In addition, hyperforin iso- methysticin, dihydromethysticin and yangonin are
lated from SJW contributes to the extract’s effects on among bioactive compounds found in Kava [79] .
afferent excitability and neurotransmission. This com- Recent studies on the mechanisms of action for isolated
pound enhances the extracellular levels of serotonin, kavalactoneshaverevealedactivitieson38/nuclearfac-
dopamine, noradrenaline, GABA and L-glutamate tor-kappaB/cyclo-oxygenase 2 signalling pathway [80].
[62,63].Itisthoughtthathyperforinactivatesnonselec- Kava produces blockade of voltage-gated ion channels,
tive cation transient receptor potential (TRP) channel wherein methysticin and kavain bind to sodium chan-
TRPC6 to increase intracellular sodium and calcium nel in its inactivated state and prolong its inactivation
content, thereby reducing neurotransmitter reuptake [81].KavalactonesalsoinhibitMAO-B[82]andblocked
[64,65]. Many clinical studies have shown antidepres- the in vitro uptake of noradrenaline into synaptosomes
sant activity of H. perforatum [66–69]. However, there prepared from the cerebral cortex and the hippocampus
are great controversies between the results presented. of the rat [83]. In addition, Wu et al. [84] showed
This may be due to different inclusion criteria, sample inhibitory activities of COX-1 and COX-2 from the dihy-
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 8

Anxiety, depression and medicinal plants 205
drokavainandyangonin.Aclinicalstudycarriedoutin Pimentapseudocaryophyllus(Gomes)l.R.Landrum:
1996 by Lehmann and collaborators [85] had demon- frompopularreportstothebench
strated the efficacy of Kava extract vs. placebo in Pimenta pseudocaryophyllus popularly known as pau-
patients with states of anxiety. In 2013, Sarris et al. cravo, louro-cravo, louro, craveiro among others
[86] also showed a significant reduction in anxiety for [108,109] remains one of the classical examples of
thekavagroupcomparedwiththeplacebogroup.How- plant species in recent time that was carefully selected
ever, in recent years several reports indicate possible on the basis of its folkloric application as a calming
hepatotoxicityassociatedwithkava[87]. agent and nerve tonic [110–114]. Collection, identifica-
tion and preparation of organic leaf extract of this spe-
Valeriana officinalis L. (Valerian) cies were followed by isolation of secondary metabolites
Valeriana officinalis possesses moderate sedative and [108] prior to chemical modifications [115]. General
sleep-promoting effect. It is being used in the treat- pharmacological test was conducted to verify beha-
ment of sleep and anxiety disorders [88–90]. The use vioural alterations, determine appropriate route of
of Radix Valerianae is described in the World Health administration, estimate dose and potential toxic effects
Organization Monographs on Selected Medicinal Plants of the ethanolic leaf extract on the animals [116]. The
(1999), European Pharmacopoeia (1998), American crude extract shows CNS activity [116]. The crude
Herbal Pharmacopoeia (1999) and European Medici- extract was partitioned with increasing polarity of sol-
nes Agency (2006) as a mild sedative and sleep-pro- vent to obtain Hexane, dichloromethane (DF), ethyl
moting agent in addition to the treatment of nervous acetate and aqueous fractions [117]. The fractions
excitation and anxiety-induced sleep disturbances [91– were subjected to pharmacological screening [open
94]. In UK, at least 25 products contain valerian and field, light–dark box (LDB), elevated plus maze (EPM),
over 400 products in Germany contain this compound tail suspension and forced swimming test (FST)] as
[95]. The anxiolytic activity of valerian has been asso- described above. The DF which showed the most
ciated with the presence of some monoterpenes and promising anxiolytic- and/or antidepressant-like activi-
sesquiterpenes [96]. Valerenic acid and valerenol ties was further investigated for possible mechanisms of
enhance the response to multiple types of recombinant actions that are involved.
GABA receptors [97,98]. Many clinical trials on the Considering the anti-anxiety and antidepressant-
A
efficacy of valerian extract have shown its potential like activities of DF, the fraction was subjected to fur-
for the treatment of sleep and anxiety disorders ther phytochemical analysis. Oleanolic acid and
[90,99,100]. methyl isoeugenol among others were isolated [116].
These isolates demonstrated antidepressant-like activi-
Cimicifuga racemosa L. (Nutt.) Black cohosh ties in male Swiss albino mice [7]. The plurality of
Regulatory bodies have included the use of C. racemosa biological activities and mechanism of oleanolic acids
L. (Nutt.) for depressive mood swings among other are considered to be limiting factors to its therapeutic
indications [57,101–103]. Several studies on C. race- application [7,118,119]. Meanwhile, susceptibility of
mosa (black cohosh) have reported its application for this triterpene to chemical modification makes it an
menopause-related anxiety disorder [104,105]. The important substrate for the development of new drug
standard extract of C. racemosa contains triterpene gly- with potential anti-anxiety and antidepressant.
cosides (cimicifugoside, 23-epi-26-deoxyactein and Oleanolic acid acrylate, methacrylate, methyl fuma-
actein), aromatic acids (salicylic acid and ferulic acid), rate and ethyl fumarate were synthesized through a
tannins, resins, phytosterols and fatty acids. Recently, single-step esterification of oleanolic acid with appro-
Nx-methylserotonin was identified in the roots/rhi- priate acyl chloride [115]. These oleanolic acid
zomes of C. racemosa as a potent agonist of serotonin derivatives were subjected to open field and FSTs.
5-HT and 5-HT receptors [106]. Despite the exten- Oleanolic acid acrylate elicits antidepressant-like effect
1A 7
sive use of C. racemosa especially during menopause, [115]. Together, the ethnopharmacological survey
clinical studies did not show significant anxiolytic effect and preclinical data on the crude extract, fractions
of black cohosh as compared to placebo. The small and isolates of P. pseudocaryophyllus demonstrate
sample size, choice of black cohosh preparation and strategic planning towards the development of phy-
dose used may have been the limiting factors in these tomedicine with anxiolytic and/or anti-anxiety
studies [107]. property (ies).
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 9

.noisserpedro/dnayteixnafotnemtaertehtrofdesustnalplanicidemtuobanoitamrofnidezirammuS
IIIelbaT
fomsinahceM
lacideM
demialccaylralupoP
stceffeedis/snoitatimiL
selpicnirpevitcA
noitca
noitpircserp
noitaraperpdnatceffe
ecnerruccO
stnalplanicideM
rostceffeedistuohtiW
dicaciniramsoR
tarforotibihnI
roftnemtaerT
gnicnahne-yromeM
noigernaenarretideM
silanicfifoassileM
yticixotfosmotpmys
,sdionepretirtehtdna
ABAGniarb
ngineb
dlim,seitreporp
aisAnretseW,]021[
)eaecaimaL(.L
]921[
dnadicacilosru
esanimasnart
,snoitatiplap
diapeelsdnaevitades
nretsew-htuos,]121[
]821[dicacilonaelo
]821,421,321[
asadna
tnemtaerT.]521,421[
nrehtroNdnaairebiS
gnisimorp
dnanoisserpedfo
oslasitI.]221[acirfA
cityloixna
]621[noisnetsuovren
ediwdlrowdetavitluc
]721[gurd
]321,221[
tnatimocnoC
dnasenepretirT
ehtnitcA
fotnemtaerT
larenegfotnemtaerT
,aigroeG;aciremAhtroN
asomecaraguficimiC
ynahtiwnoitartsinimda
fosevitavired
sumalahtopyh
fosmotpmys
suovren,sialam
dnaoiratnOothtroN
ttuN.L
noitacidemfoepyt
]231[senovafl
.ertnecrotomosav
,esuaponem
eniretu,sredrosid
dnasasnakrAottseW
)eaecalucnunaR(
dediovaebdluohs
dnaovivnirehtO
dnayteixna
sallewsa,sredrosid
]031[nisnocsiW
ehtfoesuaceb
seidutsortivni
noisserped
tnettimretnietatilicafot
gnisaercnifoytilibissop
aetacidni
]131,031[
snoitcartnoceniretu
elbaliavaoibeht
cigrenimapod
]031[ruobalgnirud
sgurdfonoitartnecnoc
]231[tceffe
eudsisihT.doolbehtni
fonoisserppuseht
aguficimiCyb4A3PYC
]331[asomecar
dnaloolaniL
htiwnoitcaretnI
sessenllifotnemtaerT
lartneCdnaocixeM
snecsecualgaestiL
]431[enenip-b
cigrenotoreseht
lartnecehtotdetaler
]431[aciremA
)eaecaruaL(
,srotpecerA1TH-5
]531[metsyssuovren
dna-a
2
srotpeconerda-b cigrenimapoddna ]431[
Dsrotpecer 1
ehtfonoitcudnI
dnanicirepyH
rotibihnievitceleS
fotnemtaerT
,aiglaruenfotnemtaerT
,aisAnisruccotub,eporuE
mutarofrepmucirepyH
fomsilobatem
]731,16[nirofrepyh
dnaA-OAMfo
,yteixna
sasredrosiddoom
htroNdnaacirfAnrehtroN
)eaecacirepyH(L
deretsinimdaoc
noitibihnI;B-OAM
dnanoisserped
dnasisoruen,yteixna
]631,16[aciremA
tiesuacebsnoitacidem
ADdnaEN,TH-5fo
]731[ainmosni
etaredom-ot-dlim
niatrecetaitnetopyam
fotsinogatna;ekatpu
]631[noisserped
ehtfosemyzne
;srotpecerADMN
]631[054Pemorhcotyc
snoitcaretnietaredom
ABAGehthtiw
A
.]631[rotpecer
ehtfonoisserppuS
nikuelretnifoesaeler
]731[6
206 J.O. Fajemiroye et al.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 10

deunitnoC
.IIIelbaT
fomsinahceM
lacideM
demialccaylralupoP
stceffeedis/snoitatimiL
selpicnirpevitcA
noitca
noitpircserp
noitaraperpdnatceffe
ecnerruccO
stnalplanicideM
.snoitcaercigrellA
lylanildnaloolaniL
tceffeekil-cityloixnA
fotnemtaerT
,noisnetfotnemtaerT
eht,snoigernaenarretideM
ailofitsugnaaludnavaL
rehtognirudsnoitatimiL
]371,271[etateca
A1TH-5hguorhtylekil
noisserped
,sredrosidsuovren
,citnaltAehtfosdnalsi
)eacaimaL(.lliM
stneitapnirosessenlli
]041[srotpecer
]931,831[
dnayteixna
,aidnI,natsikaP,yekruT
nagrocfiicepshtiw
]931,831[noisserped
nrehtuoSdnanrehtroN
.noitcnufsyd
eht,aisenorciM,acirfA
rehtohtiwsnoitcaretnI
airagluB,alusninePnaibarA
rosbreh
]831[aissuRdna
]831[slacituecamrahp lacigoloibfoytilarulpehT
lonegueosilyhtem-)E(
ytivitcaekil-cityloixnA
citeruida,tceffegnihtooS
]611[lizarB
atnemiP
msinahcemdnaseitivitca
]611[dicacilonaelodna
TH-5sevlovnitaht
tnegacaisidorhpadna
sullyhpoyracoduesp
A1
erasdicacilonaelofo
]611[rotpecer
tnegagnimlaC.]611[
murdnaL.R.L)semoG(
ebotderedisnoc
]011[cinotevrendna
)eaecatryM(
stiotsrotcafgnitimil noitacilppacituepareht ]241,141,911,811,7[
,lotinip-d,enirhpeniperoN
-tnasserpeditnaehT
noisserpedfotnemtaerT
]341[lizarB
acidupasomiM
,loretsotis-b
detaidemsitceffeekil
eht(ainmosnidna
)eaecabaF(
]541[enisomim
cigrenotoresehtyb
deirdfonoisufni
]441[metsys
]441[)sevael
enianona,eninedoiriL
tceffeekil-tnasserpeditnA
,yteixna-itnA
nrehtroN,ureP,rodaucE
alomirehcanonnA
]741[enireficunrondna
niesaercnihguorht
dnatnasluvnocitna
dnaaciremAhtuoS
)eaecanonnA(.lliM
cigrenimaonom
gniziliuqnart
]641[aciremAlartneC
]741[noissimsnartoruen
]741[seitreporp
larbeplap,niap,aeohrraiD
cillag,]841[nitecreuQ
ekil-tnasserpeditnaehT
ehtfotnalumitS
lartneCdnaocix(cid:1)eM
.vaCadiculsetegaT
dnanoitcereolip,sisotp
]941[dicacieffac,dica
ybdetaidemsitceffe
,metsysenummi
]841[aciremA
)eaecaretsA(
]941[)gniraet
A2TH-5dnaA1TH-5
,yteixna-itna
]841[srotpecer
noisserpeditna
]941,841[
edisoculg-O-7-nitecacA
tceffeekil-cityloixnaehT
suovrenfeileroT
htroNdnaaisA
anacixemehcatsagA
-b-O-7-nitecaca,)ninailit(
enosa,ninailitehtfo
sadnanoitidnoc
]051[aciremA
anacixeM.psbus
;edisoculg–)lynolam-O-″6(-d
stneutitsnocrojamehtfo
]051[reziliuqnart
)eaecaimaL(
-O-″6(-d-b-O-7-niloetul
detaidemsianacixem.Ani
]051[edisoculg–)lynolam
,sDZB/
ABAGehtyb
A ]151[rotpecer
edisoculg-O-7-nitecacA
devlovnisiytivitcacigreABAG
suovrenfeileroT
htroNdnaaisA
anacixemehcatsagA
-O-7-nitemsoid,)ninailit(
tceffeekil-cityloixnaehtni
sadnanoitidnoc
]051[aciremA
anaiztocoloX.psbus
–)lynolam-O-″6(-d-b
tneutitsnoceno,ninailitfo
]051[reziliuqnart
)eaecaimaL(
]051[;edisoculg
]251[anacixem.Aehtfo
Anxiety, depression and medicinal plants 207
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 11

deunitnoC
.IIIelbaT
fomsinahceM
lacideM
demialccaylralupoP
stceffeedis/snoitatimiL
selpicnirpevitcA
noitca
noitpircserp
noitaraperpdnatceffe
ecnerruccO
stnalplanicideM
,gnitimov,aesuanereveS
,nixetiv,nitneiroosi,nitneirO
dna
ABAGehtfotsinogA
fotnemtaerT
yteixnafotnemtaerT
]07[aciremAhtroN
atanracniaroflissaP
A
degnolorp,ssenisword
]37,07,27[nisyrhcdnanixetivosi
]07[srotpecerBABAG
dezilareneg
ainmosni,redrosid
fosedosipednaTQ
redrosidyteixna
]75[
ralucirtnevdeniatsusnon
,]07[)DAG(
]07[aidracyhcat
suoicocerp esuaponem ,smotpmys ,ainmosni
regna,noisserped
]351[sehcadaehdna
yticixototapehelbissoP
,niavakordyhid,niawaK
B-OAMtibihnisenotcalavaK
yteixnafotnemtaerT
,noisserpedfotnemtaerT
]97[cfiicaPhtuoS
mucitsyhtemrepiP
]78[
,nicitsyhtem
ortivniehtdekcolbdna]28[
]68,58[
dnaainmosni,yteixna
retsoF.G
dnanicitsyhtemordyhid
]38[enilanerdaronfoekatpu
noitnetta
]97[eninognay
ytivitcarepyh/ticfied
]87[dibromocredrosid
nwonkerasesodegraL
dnadicacinerelaV
lonerelavdnadicacinerelaV
dnapeelsfotnemtaerT
dnapeelsfotnemtaerT
htroNdnaaisA,eporuE
.LsilanicfifoanairelaV
lawardhtiwesuacot
]89,79[lonerelav
otesnopserehtecnahne
sredrosidyteixna
]09–88[sredrosidyteixna
]451[aciremA
suounitnoC.smotpmys
fosepytelpitlum
]001,99,09[
nitluseryamesu
AABAGtnanibmocer
]451[ycnedneped
]89,79[srotpecer
208 J.O. Fajemiroye et al.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 12

Anxiety, depression and medicinal plants 209
Table III presents information about some species of activity, which could provide a false-positive result (as
medicinal plants used for treatment of anxiety and/or in the case of stimulant) in the FST. Tail suspension
depression, highlighting aspects of the occurrence, test (TST) is another highly validated test for the inves-
ethnopharmacology, mechanisms of action of the tigation of antidepressant-like property of drugs [170].
extract or phytochemicals and medical prescriptions, Like antidepressant drugs, psychostimulants also
when applicable. reduce immobility in this model. The TST shares a sim-
ilar basic principle with FST in that animals develop an
Evaluation of putative anxiolytic effects of immobile posture when placed in an inescapable stress-
medicinal plants ful situation after initial escape-oriented movements.
Animal models play a central role in all areas of Acute administration of an antidepressant drug prior
biomedical research. To investigate anxiolytic effect of to the exposure of the experimental subject to the TST
crude extract or active principles from medicinal plants, prolonged active escape-directed behaviours [171].
a wide range of behavioural testing has been developed
[155–157]. Some well-established tests of anxiety
CONCLUSIONS
include open field test. This test was originally intro-
duced as a measure of emotional behaviour in rats and Current pharmacological approaches to the manage-
later adapted to mice [158–160]. Parameters such as ment of anxiety and depression are yet to engender
ambulation, time and crossing at the centre of the desirable results in clinical practice. Some of the first-
open field, grooming, freezing and rearing are often line and new medications that apparently fall into the
measured. Light–dark box (LDB) has also been used to existing classes of drugs are still associated with side
investigate anxiolytic properties. The underlining prin- effects. Medicinal plants provided ample opportunities
ciple of LDB model is based on the aversion of rodents for the development of anti-anxiety and antidepressant
to brightly illuminated areas, novel environment and drugs. The acceptance of herbal medicines for the
light-induced mild stress [161,162]. The number of treatment of these mental disorders has grown as a
transitions between the two compartments and the result of the improvements in their quality. Standard-
time spent in the light area are recorded over a speci- ization of extracts and plant isolate, adequate scientific
fied period [156]. Elevated plus maze is another widely data on safety and efficacy, preservation of medicinal
used behavioural model with a strong predictive valid- plant’s diversity, appropriate legislation and regulatory
ity to measure the anxiolytic-like effect of a novel com- agencies are still critical steps to the development of
pound [163–166]. The time spent and the number of anti-anxiety and antidepressant phytomedicine.
entries with all four paws inside the open arms are
well-established parameters for assessing anxiolytic or
ACKNOWLEDGEMENTS
anxiogenic property of new drugs. The open and closed
arms are considered to evoke the same exploratory The authors thank FAPEG, CAPES and CNPq for the
drive; therefore, avoidance of the open arms is consid- study fellowship.
ered to be a result of the induction of higher levels of
fear [164]. Other models such as marble-burying [167]
CONFLICTS OF INTEREST
and hole board tests with repetitive tendency have
been used to evaluate anxiolytic- or anxiogenic-like The authors have no conflict of interests to declare.
effects.
ABBREVIATIONS
Evaluation of putative antidepressant effects of
medicinal plants 5-HT – 5-hydroxytryptamine
Forced swimming test is the most widely used pharma- ANVISA – Agency of Sanitary Surveillance
cological test for assessing antidepressant activity ATCA – atypical tricyclic antidepressants
[168]. The FST involves the scoring of active (swim- BZD – benzodiazepine
ming and climbing) or passive (immobility) behaviour. CNS – central nervous system
Reduction in immobility is interpreted as an antidepres- CAM – complementary and alternative medicine
sant-like effect [169] of the extracts/compounds being DA – dopamine
tested provided it does not increase general locomotor DF – dichloromethane fraction
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 13

210 J.O. Fajemiroye et al.
EMA – European Medicines Agency diseases,injuriesandriskfactorsin1990–2020and
FDA – Food and Drug Administration projectedto2020.HarvardUniversityPress,Boston,MA,
FST – forced swimming test 1996.
GABA – c-aminobutyric acid 13 Diagnosticandstatisticalmanualofmentaldisorders,4th
edn,TextRevisionDSM-IV-TR,AmericanPsychiatric
MAOI – Monoamine oxidase inhibitor
Association,USA,2000.
MPC – medial prefrontal cortex
14 NestlerE.J.,BarrotM.,DiLeoneR.J.,EischA.J.,GoldS.J.,
NDRI – norepinephrine–dopamine reuptake inhibitor MonteggiaL.M.Neurobiologyofdepression.Neuron(2002)
NE – norepinephrine 3413–25.
NET – norepinephrine transporter 15 WayneC.D.,JosephL.P.,MauraL.F.Brainstructuraland
SERT – serotonin transporter functionalabnormalitiesinmooddisorders:implicationsfor
SNRI – serotonin–norepinephrine reuptake inhibitor neurocircuitrymodelsofdepression.BrainStruct.Funct.
(2008)21393–118.
SSRI – selective serotonin reuptake inhibitor
16 DumanR.S.,MonteggiaL.M.Aneurotrophicmodelfor
SJW – St. John’s Wort
stress-relatedmooddisorders.Biol.Psychiatr.(2006)59
TST – tail suspension test 1116–1127.
TCA – tricyclic antidepressants 17 PalazidouE.Theneurobiologyofdepression.Br.Med.Bull.
TM – traditional medicine (2012)101127–145.
TRP – transient receptor potential 18 DrevetsW.C.Orbitofrontalcortexfunctionandstructurein
depression.Ann.N.Y.Acad.Sci.(2007)1121499–527.
WHO – World Health Organization
19 McEwenB.S.,GianarosP.J.Centralroleofthebraininstress
andadaptation:linkstosocioeconomicstatus,health,and
REFERENCES disease.Ann.N.Y.Acad.Sci.(2010)1186190–222.
20 Castr(cid:1)enE.Ismoodchemistry?Nat.Rev.Neurosci.(2005)6
1 FerryS.,Baltassat-MilletF.Laprospectiondesplantes 241–246.
medicinales.LyonPharmaceutique.(1997)28257–260. 21 Tatarczyn^askaE.,Koodzina^skaA.,Chojnacka-Woa^jcikE.
2 SoejartoD.D.Biodiversityprospectingandbenefit-sharing: etal.Potentialanxiolytic-andantidepressant-likeeffectsof
perspectivesfromthefield.J.Ethnopharmacol.(1996)511–16. MPEP,apotent,selectiveandsystemicallyactivemGlu5
3 WilliamsonE.M.,OkpakoD.T.,EvansF.J.Selection, receptorantagonist.Br.J.Pharmacol.(2001)1321423–
preparationandpharmacologicalevaluationofplant 1430.
material.J.Med.Chem.(1996)401559–1559. 22 SchechterL.E.,RingR.H.,BeyerC.E.etal.Innovative
4 AlbuquerqueU.P.,HanazakiN.Aspesquisasetnodirigidasna approachesforthedevelopmentofantidepressantdrugs:
descobertadenovosfa(cid:1)rmacosdeinteressem(cid:1)edicoe currentandfuturestrategies.NeuroRx(2005)2590–611.
farmac^eutico:fragilidadeseperspectivas.Rev.Bras.
23 MorenoR.A.,MorenoD.H.,SoaresM.B.M.Psicofarmacologia
Farmacogn.(2006)16678–689. deantidepressivos.Rev.Bras.Psiquiatr.(1999)2124–40.
5 CryanJ.F.,SweeneyF.F.Theageofanxiety:roleofanimal 24 Bezchlibnyk-ButlerK.Z.,JeffriesJ.J.Clinicalhandbookof
modelsofanxiolyticactionindrugdiscovery.Br.J. psychotropicdrugs,9thedn.Hogrefe&HuberPublishers,
Pharmacol.(2011)1641129–1261. Toronto,Canada,1999.
6 OverstreetD.H.Modelingdepressioninanimalmodels. 25 KennedyS.H.,LamR.W.,CohenN.L.,RavindranA.V.,
MethodsMol.Biol.(2012)829125–144. CANMATDepressionWorkGroup.Clinicalguidelinesforthe
7 FajemiroyeJ.O.,GaldinoP.M.,FlorentinoI.F.etal.Plurality treatmentofdepressivedisorders.Medicationandother
ofanxietyanddepressionalterationmechanismbyoleanolic biologicaltreatments.Can.J.Psychiatry(2001)4638–58.
acid.J.Psychopharmacol.(2014)28923–934. 26 RavindranL.N.,SteinM.B.Thepharmacologictreatmentof
8 SeligmanM.E.P.,WalkerE.F.,RosenhanD.L.Abnormal anxietydisorders:areviewofprogress.J.Clin.Psychiatry
psychology.W.W.Norton&Company,NewYork,2001. (2010)71839–854.
9 SmithM.AnxietyAttacksandDisorders:GuidetotheSigns, 27 MaxwellR.A.,EckhardtS.B.Iproniazid.DrugDiscovery.
Symptoms,andTreatmentOptions.In:HelpGuidewebsite.2008. (1990)615143–154.
[Online]2009.www.helpguide.org/mental/anxiety_types_ 28 TurcotteJ.E.,DebonnelG.,MontignyC.,HebertC.,BlierP.
symptoms_treatment.htm(accessed3March2009). Assessmentoftheserotoninandnorepinephrinereuptake
10 MauroV.M.,MurrayB.S.Qualityoflifeinindividualswith blockingpropertiesofduloxetineinhealthysubjects.
anxietydisorders.Am.J.Psychiatry(2000)157669–682. Neuropsychopharmacology(2001)24511–521.
11 CMUInstitute.Treatingdepressionandanxietyinprimary 29 StahlS.M.Basicpsychopharmacologyofantidepressants,pt
care.PrimCareCompanionJ.Clin.Psychiatry.(2008)10 1:antidepressantshavesevendistinctmechanismsofaction.
145–152. J.Clin.Psychiatry(1998)595–14.
12 LopezA.D.,MurrayC.J.Theglobalburdenofdisease:a 30 BaldessariniR.J.Drugsandthetreatmentofpsychiatric
comprehensiveassessmentofmortalityanddisabilityfrom disorders:depressionandanxietydisorders,in:Hardman
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 14

Anxiety, depression and medicinal plants 211
J.G.,LimbirdL.E.(Eds),Goodman&Gilman’sthe 49 LiH.T.,WuH.M.,ChenH.L.,LiuC.M.,ChenC.Y.The
pharmacologicalbasisoftherapeutics,McGraw-Hill,New pharmacologicalactivitiesof(-)-Anonaine.Molecules(2013)
York,NY,2001,pp.447–483. 188257–8263.
31 StahlS.M.Essentialpsychopharmacology,2ndedn. 50 LiuM.,HuangH.H.,YangJ.etal.Theactivealkaloidsof
CambridgeUniversityPress,NewYork,NY,2000. GelsemiumelegansBenth.arepotentanxiolytics.
32 StahlS.M.,PradkoJ.F.,HaightB.R.,ModellJ.G.,Rockett Psychopharmacology(2013)225839–851.
C.B.,CoughlinS.L.A.Reviewoftheneuropharmacologyof 51 SasakiK.,ElOmriA.,KondoS.Rosmarinusofficinalis
bupropion,adualnorepinephrineanddopaminereuptake polyphenolsproduceanti-depressantlikeeffectthrough
inhibitor.Prim.CareCompanionJ.Clin.Psychiatry.(2004) monoaminergicandcholinergicfunctionsmodulation.
6159–166. Behav.BrainRes.(2013)23886–94.
33 Serzone[packageinsert].Bristol-MyersSquibbCompany, 52 MachadoD.G.,NeisV.B.,BalenG.O.Antidepressant-like
Princeton,NJ,2002. effectofursolicacidisolatedfromRosmarinusofficinalisL.in
34 FakimG.A.Medicinalplants:traditionsofyesterdayand mice:evidencefortheinvolvementofthedopaminergic
drugsoftomorrow.Mol.AspectsMed.(2006)271–93. system.Pharmacol.Biochem.Behav.(2012)103204–211.
35 JaricS.,MitrovicM.,DjurdjevicL.etal.Phytotherapyin 53 GaldinoP.M.,NascimentoM.V.M.,FlorentinoI.F.etal.The
medievalSerbianmedicineaccordingtothepharmacological anxiolytic-likeeffectofanessentialoilderivedfrom
manuscriptsoftheChilandarMedicalCodex(15–16th) SpirantheraodoratissimaA.St.Hil.leavesanditsmajor
centuries.J.Ethnopharmacol.(2011)137601–619. component,ß-caryophyllene,inmalemice.Prog.
36 KatiyarC.,GuptaA.,KanjilalS.,KatiyarS.Drugdiscoveryfrom Neuropsychopharmacol.Biol.Psychiatry(2012)38276–
plantsources:anintegratedapproach.Ayu(2012)3310–19. 284.
37 DukeJ.A.Medicinalplantsandthepharmaceuticalindustry, 54 OyemitanI.A.,ElusiyanC.A.,AkanmuM.A.,OlugbadeT.A.
in:JanickJ.,SimonJ.E.(Eds),Newcrops.NewYork,Wiley, Hypnotic,anticonvulsantandanxiolyticeffectsof1-nitro-2-
1993,pp.664–669. phenylethaneisolatedfromtheessentialoilofDennettia
38 WorldHealthOrganization(WHO).WHOTraditional tripetalainmice.Phytomedicine(2013)201315–1322.
MedicineStrategy(2013)542014–2023. 55 ShriR.,BhutaniK.K.,SharmaA.Anewanxiolyticfattyacid
39 Hornik-LurieT.,CwikelJ.,FeinsonM.C.,LernerY.,ZilberN. fromAethusacynapium.Fitoterapia(2010)811053–1057.
Useofunconventionaltherapiesbyprimarycarepatients– 56 KumarD.,BhatZ.A.Apigenin7-glucosidefromStachys
religiousresourcesvs.complementaryoralternativemedicine tibeticaVatkeanditsanxiolyticeffectinrats.Phytomedicine
services.Complement.Ther.Med.(2013)1517–524. (2014)211010–1014.
40 DiasA.D.,UrbanS.,RoessnerU.Ahistoricaloverviewof 57 ANVISA–Ag^enciaNacionaldeVigil^anciaSanita(cid:1)ria.
naturalproductsindrugdiscovery.Metabolites(2012)2 [Online]2014.http://portal.anvisa.gov.br/wps/content/
303–336. Anvisa+Portal/Anvisa/Inicio/Medicamentos/
41 GilaniA.H.,RahmanA.U.Trendsinethnopharmacology.J. Assunto+de+Interesse/Medicamentos+fitoterapicos(accessed
Ethnopharmacol.(2005)10043–49. 20August2014).
42 TemplemanK.,RobinsonA.Integrativemedicinemodelsin 58 EMA–EuropeanMedicinesAgency.Herbalmedicinesfor
contemporaryprimaryhealthcare.Complement.Ther.Med. humanuse.[Online]2015.Availableat:http://www.ema.
(2011)1984–92. europa.eu/ema/index.jsp?curl=pages/regulation/general/
43 LindstromA.,OoyenC.,LynchM.E.,BlumenthalC.Herb general_content_000208.jsp&mid=WC0b01ac05800240cf
supplementsalesincrease5.5%in2012:herbalsupplement (accessed02February2015).
salesrisefor9thconsecutiveyear;turmericsalesjump40% 59 EMA-EuropeanMedicinesAgency.Herbalmedicinesfor
innaturalchannel.HerbalGram.(2013)9960–65. humanuse.[Online]2015.Availableat:http://www.ema.
44 RatesS.M.K.Plantsasasourceofdrugs.Toxicon(2001)39 europa.eu/ema/index.jsp?curl=pages%2Fmedicines%
603–613. 2Flanding%2Fherbal_search.jsp&mid=WC0b01ac058001
45 CraggG.M.,NewmanD.J.Medicinalsforthemilleniathe fa1d&searchkwByEnter=false&alreadyLoaded=true&isNew
historicalrecord.Ann.N.Y.Acad.Sci.(2001)9531–25. Query=true&keyword=Enter+keywords&searchType=Latin+
46 CraggG.M.,NewmanD.J.,SnaderK.M.Naturalproductsin name+of+the+genus&taxonomyPath=&treeNumber
drugdiscoveryanddevelopment.J.Nat.Prod.(1997)60 (accessed02February2015).
52–60. 60 Ehrenshaft M., Roberts J.E., Mason R.P. Hypericin-
47 NewmanD.J.,CraggG.M.,SnaderK.M.Naturalproductsas mediated photooxidative damage of a-crystallin in human
sourcesofnewdrugsovertheperiod1981–2002.J.Nat. lens epithelial cells. Free Radic. Biol. Med. (2013) 60
Prod.(2003)661022–1037. 347–354.
48 DangH.,ChenY.,LiuX.,WangL.,JiaW.,WangY. 61 KlemowK.M.,BartlowA.,CrawfordJ.,KocherN.,ShahJ.,
Antidepressanteffectsofginsengtotalsaponinsintheforced RitsickM.MedicalattributesofSt.John’sWort(Hypericum
swimmingtestandchronicmildstressmodelsofdepression. perforatum),in: BenzieI.F.F.,SissiW.G.(Eds),Herbal
Prog.Neuropsychopharmacol.Biol.Psychiatry(2009)33 medicine:biomolecularandclinicalaspects,2ndedn, CRC
1417–1424. Press/Taylor&Francis,BocaRaton(FL),pp.1–27.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 15

212 J.O. Fajemiroye et al.
62 KaehlerS.T.,SinnerC.,ChatterjeeS.S.,PhilippuA. 77 SinghY.N.,SinghN.N.Therapeuticpotentialofkavainthe
Hyperforinenhancestheextracellularconcentrationsof treatmentofanxietydisorders.CNSDrugs(2002)16
catecholamines,serotoninandglutamateintheratlocus 731–743.
coeruleus.Neurosci.Let.(1999)262199–202. 78 SarrisJ.,KeanJ.,SchweitzerJ.,LakeJ.H.Complementary
63 VanceK.M.,RibnickyD.M.,HermannG.E.,RogersR.C.St. medicines(herbalandnutritionalproducts)inthetreatment
John’sWortenhancesthesynapticactivityofthenucleusof ofAttentionDeficitHyperactivityDisorder(ADHD):a
thesolitarytract.Nutrition(2014)3037–42. systematicreviewoftheevidence.Complement.Ther.Med.
64 LeunerK.,KazanskiV.,Mu€ellerM.etal.Hyperforin–akey (2011)19216–227.
constituentofSt.John’swortspecificallyactivatesTRPC6 79 TeschkeR.,LebotV.Proposalforakavaquality
channels.FASEBJ.(2007)214101–4111. standardizationcode.FoodChem.Toxicol.(2011)49
65 SingerA.,WonnemannM.,Mu€llerW.E.Hyperforin,amajor 2503–2516.
antidepressantconstituentofst.John’swort,inhibits 80 TzengY.M.,LeeM.J.Neuroprotectivepropertiesof
serotoninuptakebyelevatingfreeintracellularNa+.J. kavalactones.NeuralRegen.Res.(2015)10875–877.
Pharmacol.Exp.Ther.(1999)2901363–1368. 81 SchirrmacherK.,BusselbergD.,LangoschJ.M.,WaldenJ.,
66 GroblerA.C.,MatthewsG.,MolenberghsG.Theimpactof WinterU.,BingmannD.Effectsof((cid:1))-kavainonvoltage-
missingdataonclinicaltrials:are-analysisofaplacebo activatedinwardcurrentsofdorsalrhizomeganglioncells
controlledtrialofHypericumperforatum(StJohnswort)and fromneonatalrats.Eur.Neuropsychopharmacol.(1999)9
sertralineinmajordepressivedisorder.Psychopharmacology 171–176.
(2014)2311987–1999. 82 UebelhackR.,FrankeL.,ScheweH.J.Inhibitionofplatelet
67 SarrisJ.,FavaM.,SchweitzerI.,MischoulonD.StJohn’s MAO-Bbykavapyrone-enrichedextractfromPiper
Wort(Hypericumperforatum)versussertralineandplaceboin methysticumFoster(kava-kava).Pharmacopsychiatry
majordepressivedisorder:continuationdatafroma26-week (1998)31187–192.
RCT.Pharmacopsychiatry(2012)45275–278. 83 SeitzU.,SchulleA.,GleitzJ.[3H]-monoamineuptake
68 LindeK.,RamirezG.,MulrowC.D.,PaulsA., inhibitionpropertiesofkavapyrones.PlantaMed.(1997)63
WeidenhammerW.,MelchartD.StJohn’swortfor 548–549.
depressionanoverviewandmeta-analysisofrandomised 84 WuD.,YuL.,NairM.G.,DeWittD.L.,RamsewakR.S.
clinicaltrials.BMJ(1996)313253–258. Cyclooxygenaseenzymeinhibitorycompoundswith
69 LindeK.,Knu€ppelL.Large-scaleobservationalstudiesof antioxidantactivitiesfromPipermethysticum(kava-kava)
hypericumextractsinpatientswithdepressivedisorders–a roots.Phytomedicine(2002)941–47.
systematicreview.Phytomedicine(2005)12148–157. 85 LehmannE.,KinzlerE.,FriedemannJ.Efficacyofaspecial
70 MiroddiM.,CalapaiG.,NavarraM.,MinciulloP.L.,Gangemi Kavaextract(Pipermethysticum)inpatientswithstatesof
S.PassifloraincarnataL.:ethnopharmacology,clinical anxiety,tensionandexcitednessofnon-mentalorigin–a
application,safetyandevaluationofclinicaltrials.J. double-blindplacebo-controlledstudyoffourweeks
Ethnopharmacol.(2013)150791–804. treatment.Phytomedicine(1996)3113–119.
71 NascimentoD.F.,SantanaA.P.M.,LeiteI.O.et al.Clinical 86 SarrisJ.,StoughC.,BousmanC.A.etal.Kavainthe
toxicologystudyofanherbalmedicinewithPassiflora treatmentofgeneralizedanxietydisorder:adouble-blind,
incarnataL.,CrataegusoxyacanthaL.,SalixalbaL.in randomized,placebo-controlledstudy.J.Clin.
healthyvolunteers.Rev.Bras.Farmacogn.(2009)19 Psychopharmacol.(2013)33643–648.
261–268. 87 KetolaR.A.,ViinamakiJ.,RasanemI.,PelanderA.,Goebeler
72 MarchartE.,KrennL.,KoppB.Quantificationofthe S.Fatalkavalactonesintoxicationbysuicidalintravenous
flavonoidglycosidesinPassifloraincarnatabycapillary injection.ForensicSci.Int.(2015)2497–11.
electrophoresis.PlantaMed.(2003)69452–466. 88 PinheiroM.L.P.,Alca^ntaraC.E.P.,MoraesM.,AndradeE.D.
73 SundaraganesanN.,MariappanG.,ManoharanS.Molecular ValerianaofficinalisL.forconscioussedationofpatients
structureandvibrationalspectroscopicstudiesofChrysin submittedtoimpactedlowerthirdmolarsurgery:a
usingHFandDensityFunctionalTheory.Spectrochim.Acta randomized,double-blind,placebo-controlledsplit-mouth
PartAMol.Biomol.Spectrosc.(2012)8767–76. study.J.Pharm.Bioallied.(2014)6109–114.
74 ZanoliP.,AvalloneR.,BaraldiM.Behavioral 89 KennedyD.O.,LittleW.,HaskellC.F.,ScholeyA.B.
characterizationoftheflavonoidsapigeninandChrysin. AnxiolyticeffectsofacombinationofMelissaofficinalisand
Fitoterapia(2000)71117–123. Valerianaofficinalisduringlaboratoryinducedstress.
75 BrownE.,HurdN.S.,McCallS.,CeremugaT.E.Evaluationof Phytother.Res.(2006)2096–102.
theanxiolyticeffectsofchrysin,aPassifloraincarnata 90 SchmitzM.,Ja€ckelM.Comparativestudyforassessing
extract,inthelaboratoryrat.AANAJ.(2007)75333–337. qualityoflifeofpatientswithexogenoussleepdisorders
76 WolfmanC.,ViolaH.,PaladiniA.,DajasF.,MedinaJ.H. (temporarysleeponsetandsleepinterruptiondisorders)
Possibleanxiolyticeffectsofchrysin,acentral treatedwithahops-valarianpreparationanda
benzodiazepinereceptorligandisolatedfromPassiflora benzodiazepinedrug.Wien.Med.Wochenschr.(1998)148
coerulea.Pharmacol.Biochem.Behav.(1994)471–4. 291–298.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 16

Anxiety, depression and medicinal plants 213
91 WHO–WorldHealthOrganization.Monographsonselected 107 AmsterdamJ.D.,YaoY.,MaoJ.J.Randomized,double-blind,
medicinalplants(1999)1267–276. placebo-controlledtrialofCimicifugaracemosa(blackcohosh)
92 EuropeanPharmacopoeia.Valerianroot,3rdedn.Councilof inwomenwithanxietydisorderduetomenopause.J.Clin.
EuropeDepfortheQualityofMedicines,Strasbourg,1998. Psychopharmacol.(2009)29478–483.
93 AmericanHerbalPharmacopoeia.Valerianroot.Valeriana 108 PaulaJ.A.M.,PaulaJ.R.,BaraM.T.F.,RezendeM.H.,
officinalis.Analytical,qualitycontrolandtherapeutic FerreiraH.D.Estudofarmacogno(cid:1)sticodasfolhasdePimenta
monograph,in:RoyUpton.(Ed.),Americanherbal pseudocaryophyllus(Gomes)L.R.Landrum–Myrtaceae.Rev.
pharmacopoeiaandtherapeuticcompendium,CSS Bras.Farmacogn.(2008)18265–278.
Associates,USA,1999,pp.13–18. 109 PaulaJ.A.M.,FerriP.H.,BaraM.T.F.,TresvenzolL.M.F.,Sa(cid:1)
94 EMA-EuropeanMedicinesAgency.Herbalmedicinesfor F.A.S.,PaulaJ.R.Infraspecificchemicalvariabilityinthe
humanuse.CommunityHerbalMonographonValeriana essentialoilsofPimentapseudocaryophyllus(Gomes)L.R.
officinalisL.,Radix,2006. Landrum(Myrtaceae).Biochem.System.Ecol.(2011)39
95 HoughtonP.J.Thescientificbasisforthereputedactivityof 643–650.
valerian.J.Pharm.Pharmacol.(1999)51505–512. 110 LandrumL.R.Floraneotropica:monograph45
96 KennedyD.O.,WightmanE.L.Herbalextractsand Campomanesia,Pimenta,Blepharocalyx,Legrandia,Acca,
phytochemicals:plantsecondarymetabolitesandthe Myrrhinium,andLuma(Myrtaceae).OrganizationforFlora
enhancementofhumanbrainfunction.Adv.Nutr.(2011)2 Neotropica,NewYork,1985.
32–50. 111 Nakaoka-SakitaM.,AguiarO.T.,YatagaiM.,IgarashiT.
(cid:1) 97 BenkeD.,BarberiesA.,KoppS.etal.GABA receptorsas OleoessencialdePimentapseudocaryophyllusvar.
A
invivosubstratefortheanxiolyticactionofvalerenicacid,a pseudocaryophyllus(Gomes)Landrum(Myrtaceae)I:
majorconstituentofvalerianrootextracts. cromatografiaaga(cid:1)s/espectrometriademassa(CC/EM).Rev.
Neuropharmacology(2009)56174–181. Inst.Flor.(1994)653–61.
98 BeckerA.,FelgentreffF.,Schr€oderH.,MeierB.,Brattstro€mA. 112 LandrumL.R.,KawasakiM.L.ThegeneraofMyrtaceaein
TheanxiolyticeffectsofaValerianextractisbasedonValerenic Brazil:anillustratedsynoptictreatmentandidentification
acid.BMCComplement.Altern.Med.(2014)141–5. keys.Brittonia(1997)49508–536.
99 GharibM.,SamaniL.N.,PanahZ.E.,NaseriM.,BahraniN., 113 LimaM.E.L.,CordeiroI.,YoungM.C.M.,SobraM.E.G.,
KianiK.Theeffectofvalericonanxietyseverityinwomen MorenoP.R.H.Antimicrobialactivityoftheessentialoil
undergoinghyterosalpingography.Glob.J.Health.Sci. fromtwospecimensofPimentapseudocaryophyllus(Gomes)
(2015)7358–363. L.R.Landrum(Myrtaceae)nativefromS~aoPauloState–
100 AndreatiniR.,SartoriV.A.,SeabraM.L.,LeiteJ.R.Effectof Brazil.Pharmacologyonline(2006)3589–593.
valepotriates(valerianextract)ingeneralizedanxiety 114 SantosB.C.B.,SilvaJ.C.T.,GuerreroJu(cid:1)niorP.G.,Leita~oG.G.,
disorder:arandomizedplacebo-controlledpilotstudy. BarataL.E.S.,Isolationofchavibetolfromessentialoilof
Phytother.Res.(2002)16650–654. Pimentapseudocaryophyllusleafbyhigh-speedcounter-
101 American Herbal Pharmacopoeia Botanical currentchromatography.J.Chromatogr.(2009)1216
Pharmacognosy. Actea racemosa L. syn. Cimicifuga racemosa 4303–4306.
(L.) Nutt, in: Roy Upton. (Ed.) American herbal 115 FajemiroyeJ.O.,PolepallyP.R.,ChaurasiyaN.D.,Tekwani
pharmacopoeia botanical pharmacognosy, CRC Press, USA, B.L.,ZjawionyJ.K.,CostaE.A.Oleanolicacidacrylateelicits
2011, pp. 217–222. antidepressant-likeeffectmediatedby5-HT receptor.Sci.
1A
102 PengellyA.,BennetK.Appalachianplantmonographs. Rep.(2015)511582.
BlackcohoshActearacemosaL.,2012.http:// 116 FajemiroyeJ.O.,MartinsJ.L.R.,BritoA.F.etal.Central
www.frostburg.edu/aces/appalachian-plants/. activitiesofPimentapseudocaryophyllus(Gomes)L.R.
103 EuropeanMedicinesAgency(EMA).Assessmentreporton Landrum.IJMAP(2012)2118–122.
Cimicifugaracemosa(L.)Nutt.,rhizome,EMA,United 117 PaulaJ.A.M.,SilvaM.R.R.,CostaM.P.etal.,Phytochemical
Kingdom,2008. analysisandantimicrobial,antinociceptive,andanti-
104 BolleP.,MastrangeloS.,PerroneF.,EvandriM.G.Estrogen- inflammatoryactivitiesoftwochemotypesofPimenta
likeeffectofaCimicifugaracemosaextractsub-fractionas pseudocaryophyllus(Myrtaceae).J.Evid.Based.Complement.
assessedbyinvivo,exvivoandinvitroassays.J.Steroid Altern.Med.(2012)2012ArticleID420715,15pages.
Biochem.Mol.Biol.(2007)107262–269. 118 SpornM.B.,HondaT.,FinlayH.J.,GribbleG.W.,SuhN.,
105 Mohammad-Alizadeh-CharandabiS.,ShahnaziM.,Nahaee MichaelB.Newenonederivativesofoleanolicacidandursolic
J.,BayatipayanS.Efficacyofblackcohosh(Cimicifuga acidasinhibitorsofnitricoxideproductioninmouse
racemosaL.)intreatingearlysymptomsofmenopause:a macrophages.Bioorg.Med.Chem.Lett.(1997)71623–1628.
randomizedclinicaltrial.Chin.Med.(2013)81–7. 119 SpornM.B.,HondaT.,RoundsB.V.,GribbleG.W.,SuhN.,
106 Nikoli(cid:1)cD.,LiJ.,VanBreemenR.B.MetabolismofN- WangY.Designandsynthesisof2-cyano-3,12-dioxoolean-
methylserotonin,aserotonergicconstituentofblackcohosh 1,9-dien-28-oicacid,anovelandhighlyactiveinhibitorof
(Cimicifugaracemosa,L.(Nutt.)),byhumanlivermicrosomes. nitricoxideproductioninmousemacrophages.Bioorg.Med.
Biomed.Chromatogr.(2014)281647–1651. Chem.Lett.(1998)82711–2714.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 17

214 J.O. Fajemiroye et al.
120 SevikH.,GuneyK.EffectsofIAA,IBA,NAA,andGA3on 134 Guzm(cid:1)an-Guti(cid:1)errezS.L.,Bonilla-JaimeH.,Go(cid:1)mez-CansinoR.,
rootingandmorphologicalfeaturesofMelissaofficinalisL. Reyes-ChilpR.Linaloolandb-pineneexerttheir
stemcuttings.ScientificWorldJournal(2013)2013Article antidepressant-likeactivitythroughthemonoaminergic
ID909507,5pages. pathway.LifeSci.(2015)12824–29.
121 EmamghoreishiM.,TalebianpourM.S.Antidepressanteffect 135 Guzman-Guti(cid:1)errezS.L.,Gomez-CansinoR.,Garcia-Zebadua
ofMelissaofficinalisintheforcedswimmingtest.DARU J.C.,Jimenez-PerezN.C.,Reyes-ChilpaR.Antidepressant
(2009)1742–47. activityofLitseaglaucescensessentialoil:identificationof
122 ObulesuM.,RaoD.M.EffectofplantextractsonAlzheimer’s beta-pineneandlinaloolasactiveprinciples.J.
disease:aninsightintotherapeuticavenues.J.Neurosci. Ethnopharmacol.(2012)143673–679.
RuralPract.(2011)256–61. 136 BiliaA.R.,GalloriS.,VincieriF.F.St.John’swortand
123 TaiwoA.E.,LeiteF.B.,LucenaG.M.etal.Anxiolyticand depressionefficacy,safetyandtolerability-anupdate.Life
antidepressant-likeeffectsofMelissaofficinalis(lemonbalm) Sci.(2002)703077–3096.
extractinrats:influenceofadministrationandgender. 137 RussoE.,ScicchitanoF.,WhalleyB.J.etal.Hypericum
IndianJ.Pharmacol.(2012)44189–192. perforatum:pharmacokinetic,mechanismofaction,
124 KennedyD.O.,ScholeyA.B.,TildesleyN.T.,PerryE.K., tolerability,andclinicaldrug-druginteractions.Phytother.
WesnesK.A.Modulationofmoodandcognitiveperformance Res.(2013)28643–655.
followingacuteadministrationofMelissaofficinalis(lemon 138 ChuC.J.,KemperK.J.Lavender(Lavandulaspp.).Longwood
balm).Pharmacol.Biochem.Behav.(2002)72953–964. HerbalTaskForce,(2001)1–31.:http://www.mcp.edu/
125 KennedyD.O.,SavelevG.S.,TildesleyN.T.J.,PerryE.K., herbal/
WesnesK.A.,ScholeY.A.B.Modulationofmoodand 139 AkhondzadehS.,KashaniL.,FotouhiA.etal.Comparison
cognitiveperformancefollowingacuteadministrationof ofLavandulaangustifoliaMill.tinctureandimipramineinthe
singledosesofMelissaofficinalis(Lemonbalm)withhuman treatmentofmildtomoderatedepression:adouble-blind,
CNSnicotinicandmuscarinicreceptor-bindingproperties. randomizedtrial.Prog.Neuropsychopharmacol.Biol.
Neuropsychopharmacology(2003)281871–1881. Psychiatry(2003)27123–127.
126 GuginskiaG.,LuizA.P.,SilvaM.D.etal.Mechanisms 140 ChiocaL.R.,FerroM.M.,BarettaI.P.etal.Anxiolytic-like
involvedintheantinociceptioncausedbyethanolicextract effectoflavenderessentialoilinhalationinmice:
obtainedfromtheleavesofMelissaofficinalis(lemonbalm) participationofserotonergicbutnotGABA /benzodiazepine A
inmice.Pharmacol.Biochem.Behav.(2009)93 neurotransmission.J.Ethnopharmacol.(2013)147
10–16. 412–418.
127 AlijanihaF.,NaseriM.,AfsharypuorS.etal.Heart 141 SpornM.B.,HondaT.,HondaY.etal.Anovel
palpitationreliefwithMelissaofficinalisleafextract:double dicyanotriterpenoid,2-cyano-3,12-dioxooleana-1,9(11)-dien-
blind,randomized,placebocontrolledtrialofefficacyand 28-onitrile,activeatpicomolarconcentrationsforinhibition
safety.J.Ethnopharmacol.(2015)164378–384. ofnitricoxideproduction.Bioorg.Med.Chem.Lett.(2002)
128 AwadR.,MuhammadA.,DurstT.,TrudeauV.L.,Arnason 121027–1030.
J.T.Bioassay-guidedfractionationoflemonbalm(Melissa 142 SpornM.B.,LibyK.T.,YoreM.M.,FuL.,LopchukJ.M.,
officinalisL.)usinganinvitromeasureofGABA GribbleG.W.Newsynthetictriterpenoids:potentagentsfor
transaminaseactivity.Phytother.Res.(2009)23 preventionandtreatmentoftissueinjurycausedby
1075–1081. inflammatoryandoxidativestress.J.Nat.Prod.(2011)74
129 AkhondzadehS.,NoroozianM.,MohammadiM.,Ohadinia 537–545.
S.,JamshidiA.H.,KhaniM.Melissaofficinalisextractinthe 143 SriramN.G.S.,KavithaV.M.J.,SasikumarS.C.,RajeswariR.
treatmentofpatientswithmildtomoderateAlzheimer’s Phytochemicalscreeningandantimicrobialactivityofthe
disease:adoubleblind,randomised,placebocontrolledtrial. plantextractsofMimosapudicaL.againstselectedmicrobes.
J.Neurol.Neurosurg.Psychiatry(2003)74863–866. Ethnobot.Leafl.(2009)13618–624.
130 DogL.T.,PowellL.K.,WeismanM.S.Criticalevaluationof 144 Guzm(cid:1)an-Guti(cid:1)errezS.L.,Reyes-ChilpaR.,Bonilla-JaimeH.
thesafetyofCimicifugaracemosainmenopausesymptom Medicinalplantsforthetreatmentof“nervios”,anxiety,and
relief.MenopauseJ.(2003)10299–313. depressioninMexicanTraditionalMedicine.Rev.Bras.
131 McKennaD.J.,JonesK.,HumphreyS.,HughesK.Black Farmacogn.(2014)24591–608.
cohosh:efficacy,safety,anduseinclinicalandpreclinical 145 ZawareB.B.,ChaudhariS.R.,ShindeM.T.Anoverviewof
applications.Altern.Ther.HealthMed.(2001)793–100. MimosapudicaLinn.:chemistryandpharmacologicalprofile
132 Netfarma.Bulademedicamento.Availableat:http:// RJPBCS.(2014)5754–761.
www.netfarma.com.br/geraBula.asp?NomeArquivoBula= 146 EscribanoP.,ViruelM.A.,HormazaJ.I.Characterizationand
P00002MRJ00.pdf(accessed10August2015). cross-speciesamplificationofmicrosatellitemarkersin
133 SilvaA.G.,Branda~oA.B.,CacciariR.S.,SoaresW.H. cherimoya(AnnonacherimolaMill.,Annonaceae).Mol.Ecol.
Avan(cid:1)cosnaelucida(cid:1)ca~odosmecanismosdeac(cid:1)a~ode Notes(2004)4746–748.
Cimicifugaracemosa(L.)Nutt.nossintomasdoclimat(cid:1)erio. 147 Mart(cid:1)ınez-Va(cid:1)zquezM.,Estrada-ReyesR.,EscalonaA.G.A.
Rev.Bras.Pl.Med.(2009)11455–464. etal.Antidepressant-likeeffectsofanalkaloidextractofthe
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

## Page 18

Anxiety, depression and medicinal plants 215
aerialpartsofAnnonacherimoliainmice.J.Ethnopharmacol. 160 ArcherJ.Testsforemotionalityinratsandmice:areview.
(2012)139164–170. Anim.Behav.(1973)21205–235.
148 Bonilla-JaimeH.,Guadarrama-CruzG.,Alarcon-AguilarF.J., 161 BourinM.,Hasco€etM.Themouselight/darkboxtest.Eur.J.
Limo(cid:1)n-MoralesO.,Vazquez-PalaciosG.Antidepressant-like Pharmacol.(2003)46355–65.
activityofTageteslucidaCav.ismediatedby5-HT and 162 CrawleyJ.N.Exploratorybehaviormodelsofanxietyin
1A
5-HT receptors.J.Nat.Med.(2015)4463–467. mice.Neurosci.Biobehav.Rev.(1985)937–44.
2A
149 Guadarrama-CruzG.,Alarco(cid:1)n-AguilarF.J.,Vega-AvilaE., 163 PellowS.,ChopinP.,BrileyM.,BrileyM.Thevalidationof
Va(cid:1)zquez-PalaciosG.,Bonilla-JaimeH.Antidepressant-like open:closedarmentriesinanelevatedplus-maze:anovel
effectofTageteslucidaCav.extractinrats:involvementof testofanxietyintherat.J.Neurosci.Methods(1985)14
theserotonergicsystem.AJCM’s(2012)40753–768. 149–167.
150 Estrada-ReyesR.,Lo(cid:1)pez-RubalcavaC.,Ferreyra-CruzO.C. 164 RodgersR.J.,DalviA.Anxiety,defenseandtheelevated
etal.Centralnervoussystemeffectsandchemical plus-maze.Neurosci.Behav.(1997)21801–810.
compositionoftwosubspeciesofAgastachemexicana;an 165 CrawleyJ.N.What’swrongwithmymouse?,in:Jacqueline
ethnomedicineofMexico.J.Ethnopharmacol.(2014)153 N.Crawley.(Ed.)Behavioralphenotypingoftransgenicand
98–110. knockoutmice,2ndedn,JohnWiley&Sons,NewYork,
151 Gonza(cid:1)lez-TrujanoM.E.,Ponce-Mun~ozH.,Hidalgo-Figueroa 2007,pp.100–150.
S.,Navarrete-V(cid:1)azquezG.,Estrada-SotoS.Depressanteffects 166 Crawley J.N. Behavioral phenotyping of transgenic and
ofAgastachemexicanamethanolextractandoneofmajor knockout mice: experimental design and evaluation of
metabolitestilianin.APJTB(2015)8185–190. general health, sensory functions, motor abilities,
152 GalvezJ.,Estrada-ReyesaR.,Ben(cid:1)ıtez-KingG.etal. and specific behavioral tests. Brain Res. (1999) 835
InvolvementoftheGABAergicsystemintheneuroprotective 18–26.
andsedativeeffectsof7-O-glucosideinrodents.Restor. 167 NardoM.,CasarottoP.C.,GomesF.V.,Gumiar~aesF.S.
Neurol.Neurosci.(2015)331–18. CannabidiolreversesthemCPP-inducedincreaseinmarble-
153 FahamiF.,AsaliZ.,AslaniA.,FathizadehN.Acomparative buryingbehavior.Fundam.Clin.Pharmacol.(2014)28
studyontheeffectsofHypericumperforatumandpassion 544–550.
floweronthemenopausalsymptomsofwomenreferringto 168 PorsoltR.D.,LePichonM.,JalfreM.Depression:anew
Isfahancityhealthcarecenters.J.Nurs.MidwiferyRes. animalmodelsensitivetoantidepressanttreatments.Nature
(2010)15202. (1977)266730–732.
154 Pato(cid:3)ckaJ.,JaklJ.Biomedicallyrelevantchemical 169 SlatteryD.A.,CryanJ.F.Usingtheratforcedswimtestto
constituentsofValerianaofficinalis.J.Appl.Biomed.(2010)8 assessantidepressant-likeactivityinrodents.Nat.Protoc.
11–18. (2012)71009–1014.
155 BourinM.,Petit-Demouli(cid:1)ereB.,DhonnchadhaB.N.,Hascoet 170 Steru L., Chermat R., Thierry B., Simon P. The tail
M.Animalmodelsofanxietyinmice.Fundam.Clin. suspension test: a new method for screening
Pharmacol.(2007)21567–574. antidepressants in mice. Psychopharmacology (1985) 85
156 CrawleyJ.N.,GoodwinF.K.Preliminaryreportofasimple 367–370.
animalbehaviorfortheanxiolyticeffectsofbenzodiazepines. 171 CryanJ.F.,MombereauC.,VassoutA.Thetailsuspension
Pharmacol.Biochem.Behav.(1980)13167–170. testasamodelforassessingantidepressantactivity:review
157 FileS.E.Theuseofsocialinteractionasamethodfor ofpharmacologicalandgeneticstudiesinmice.Neurosci.
detectinganxiolyticactivityofchlordiazepoxide-likedrugs.J. Biobehav.(2005)29571–625.
Neurosci.Methods(1980)2219–238. 172 TakahashiM.,SatouT.,OhashiM.,HayashiS.,Sadamoto
158 HallC.S.Emotionalbehaviorintherat.I.Defecationand K.,KoikeK.Interspeciescomparisonofchemical
urinationasmeasuresofindividualdifferencesin compositionandanxiolytic-likeeffectsoflavenderoilsupon
emotionality.J.Comp.Psychol.(1934)18385–403. inhalation.NPC(2011)61769–1774.
159 PrutL.,BelzungC.Theopenfieldasaparadigmtomeasure 173 WoronukG.,DemissieZ.,RheaultM.,MahmoudS.
theeffectsofdrugsonanxiety-likebehaviors:areview.Eur. BiosynthesisandtherapeuticpropertiesofLavandula
J.Pharmacol.(2003)4633–33. essentialoilconstituents.PlantaMed.(2011)777–15.
ª2016Socie(cid:1)te(cid:1)Fran(cid:1)caisedePharmacologieetdeThe(cid:1)rapeutique
Fundamental&ClinicalPharmacology30(2016)198–215
14728206,
2016,
3,
Downloaded
from
https://onlinelibrary.wiley.com/doi/10.1111/fcp.12186
by
Aix-Marseille
Université,
Wiley
Online
Library
on
[27/10/2023].
See
the
Terms
and
Conditions
(https://onlinelibrary.wiley.com/terms-and-conditions)
on
Wiley
Online
Library
for
rules
of
use;
OA
articles
are
governed
by
the
applicable
Creative
Commons
License

